Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Depression 4 Neoplasms 3 Neoplasm Metastasis 3 Anxiety Disorders 3 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Opioid-Related Disorders 1 Melanoma 1 Lymphoma 1 Hospice 1 Hematopoietic and Lymphatic System Neoplasm 1 Hematologic Neoplasms 1 Gastrointestinal Neoplasms 1 Endocrine Gland Neoplasms 1 Depressive Disorder, Major 1 Depressive Disorder 1 Caregiver Distress 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Biliary Tract Neoplasms 1 Agnosia 1

Interventions

Bupivacaine 4 Saline Solution 3 Ketamine 3 Transcutaneous Electric Nerve Stimulation 2 Ropivacaine 2 Radiofrequency Ablation 2 Magnesium Sulfate 2 Ketorolac 2 Dexmedetomidine 2 Control Groups 2 Anesthesia, Local 2 Acupuncture Therapy 2 Acetaminophen 2 engage 8200 1 Yoga 1 Varenicline 1 Transdermal Patch 1 Therapeutics 1 Telemedicine 1 Surgical Instruments 1 STAMP-I protocol 1 Radiosurgery 1 Psilocybin 1 Palliative Care 1 Oxycodone 1 Music Therapy 1 Morphine 1 Methods 1 Levobupivacaine 1 Ketoprofen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Agnosia × Psilocybin × 1 year × Clear all

NCT06001749 2025-12-16

Psilocybin in Cancer Pain Study

Dana-Farber Cancer Institute

Phase 2 Recruiting

Agnosia, Opioid-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡